Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Key findings presented include: transcriptomic analyses, demonstrating Kevetrin modulation of p53 signaling pathways; and induction of cell cycle arrest and apoptosis in Ovarian Cancer cell-lines and in xenograft tumors.
In a completed Phase 1 clinical trial, Kevetrin was well-tolerated with minimal adverse effects. A Phase 2a clinical trial in Ovarian Cancer is currently underway in which similar analyses of pathway modulations by Kevetrin are being explored directly using tumor biopsies before and after treatment.
What about Ovarian cancer?
Sent 2 questions into conference@cellceutix.com so far.
One on Brilicidan materials purchased for Antibiotic and also on funding options other than dilution or partnership.
Why .60?
Could be partnership in the works for that week. Hence conference call in June. Who knows.
Don't want calm, cool, and collected. Want aggressive plan with financing.
I don't know why people sold. Tried to solicit that answer. But Leo did blow it on this one.
Several trials are expected to end this year, no?
Shelf agreement vs aspire. Would it be better to find another agreement with a company or draw from the shelf?
A new standard of care for OM and UC. How much is that worth alone?
Seems the answer is simple. PUT $30m cash on the books and questioning disappears. No doubt the B has big potential.
How significant was DrB comment on Brilacidan being used for acne?
Just would like to know if someone on this board sold more than 5k shares of ctix in last 2 days...then why?
Who sold shares in last 2 days? Would like to know reasons from those that actually sold more than 5k shares. Just wondering the logic.
From today's event, I learned how to pronounce Brilacidan and that it could be used for acne. Was expecting to hear about acceleration of trials and potentially financing options. A bit disappointed.
Thinking the prerecorded call today will highlight further the likelihood of B becoming an approved drug and because of its properties becoming a blockbuster. The company will accelerate trials and financing even at expense of P.
And who thinks Kevetrin will cure many cancers? I don't remember reading that.
My understanding is that they want to maximize any partnering deal. So, in my opinion, he will review results of trial so far, introduce new results that further validate what has been seen thus far, and then talk about financing options. Really, if results are becoming more solid, then risks of not partnering is declining.
Not sure I quite understand the harm if reverse split to uplist. Is it the time between reverse split and uplist date? Or is the time after uplist date?
If pipeline is strong and looking more promising everyday, then to me it seems there would be a "good" date to attempt it, if it means more access to capital. Would like to hear objective views from both sides.
Likely will talk about some form of financing. Doubt a license or partnership right now.
At some point soon the tide will turn and the company will partner or find another investor.
I suggest a 60 Minutes TV special. I mean a new class antibiotic and a drug that can activate P53.
What is form 424B5?
First, two different roles with AF vs Leo. AF is a writer. Second, Leo has gone above and beyond to provide accurate information albeit at times too excited.
af who? Can't trust anyone who is unable to write an balanced view in a setting such as The Street.
Wondering who has doubled their shares since the price has been below $1?
I was implying that it doesn't matter at the moment since they put it on hold to avoid larger dilution in hopes to partner. The topic and action will pick up again when they are ready.
Meanwhile, they have strong indication (at a low cost) that they can advance the pipeline. In my opinion, they are very confident in the antibiotic relative to competition that waiting can be the strategy. Maybe they should partner with the government since the lack of effective, safe antibiotics is becoming a rather large concern. Ha.
They did. But, really, does it matter? They are postponing the antibiotic development in order to prove out the anti-inflammatory properties. Furthermore, with P showing potential the cost is lower to prove/test its potential.
I would hold off on selling B until latest possible as it is starting to show efficacy and safety in multiple indications. SeLL Priusol to fund more B trials and K trials. See if Govts will help payou for B antibiotic trial.
Doesn't seem to be fretting over the stock price; looking to partner and has the funds to do it with current strategy and trial success.
$125m market cap for a company with a great pipeline is amazing. One infusion of cash OR success in the upcoming P or B trial could change things significantly.
IMO, success in the upcoming trials of P and B will dramatically change the landscape.
If results are good, then why the rush?
Not sure I understand the downward pressure of price. Is it related to the company issuing shares to public or Aspire? Or is it shareholders selling?
Bottom line for me is that prurisol is not price into the stock price and the only remaining concern for people seems to be cash position? Does that mean if the company had 100 million cash on hand that the price would be a lot higher based on pipeline status?
I find Adam rude and offensive, and I don't trust his writing because he doesn't also consider the positive aspects of CTIX. I have read the email exchange many times now along with the other communication from the company and really I don't see the issue.
Agree. Will likely purchase more tomorrow pending price action.
I think it's a good question. If CTIX had $100m on hand, would the stock valuation be different?
Agree George. Also, I believe p2 success in P is a little different than B in antibiotic for many reasons, such as trial time and safety validation. Just as I suspect a successful p2 in B-OM will allow a tailwind behind B for partnership.
And, in my opinion, if P shows efficacy at that level then share price will appreciate significantly without a partnership.
I am suggesting that if P has a strong showing at the end of this trial then we do not need to wait for a partnership IMO. I'm not 100% positive on price potential, but I do believe someone recently did a nice NPV study.